$VERA News

Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Is FDA Accelerated Approval Of TRUTAKNA Transforming The Investment Case For Vera Therapeutics (VERA)?

Vera Therapeutics (VERA) Could Be 92% Below Fair Value After FDA Approval

Vera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% Run

Vera Therapeutics: A Crowded IgAN Market Leaves No Room For A Premium (Downgrade)

Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner

TD Cowen Maintains Buy on Vera Therapeutics, Raises Price Target to $78

Guggenheim Maintains Buy on Vera Therapeutics, Raises Price Target to $76

CORRECTION: Wedbush Maintains Neutral On Vera Therapeutics, Raises Price Target To $43

HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Raises Price Target to $125

Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript

VERA Stock Surges After Drug To Treat Rare Kidney Disease Gets FDA Approval – Retail Sees The Move As Catalyst For Vera Therapeutics

Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy

B of A Securities Maintains Buy on Vera Therapeutics, Raises Price Target to $70

Why Is Vera Therapeutics Stock Gaining Tuesday?

FDA Approves Vera Therapeutics' Trutakna For Treatment Of Proteinuria In Adults With Primary Immunoglobulin A Nephropathy

Vera Therapeutics wins FDA nod for closely watched kidney disease drug

Vera Therapeutics Shares Climb Ahead of FDA Decision on Atacicept (VERA)

VERA Stock Rallies Ahead Of High-Stakes FDA Decision On Lead Kidney Disease Drug – Retail Sees 35% Potential Upside